Nine numbers in the abstract
Where each one falls
Where it lands on the map
the abstract, start to end
SGLT-2i reduced MACE (OR, 0.71; 95% CI 0.67,0.75, P<0.001) and ACM (OR, 0.53; 95% CI 0.49,0.57, P<0.001) …
… lowered the risk of HHF (OR, 0.56; 95% CI 0.46,0.68, P<0.001), MI (OR, 0.77; 95% CI 0.73,0.81, P<0.001), stroke (OR, 0.75; 95% CI 0.72,0.78, P<0.001), CVM (OR, 0.58; 95% CI 0.49,0.69, P<0.001) and HF (OR, 0.56; 95% CI 0.48,0.67, P<0.001), …
… the risk of severe hypoglycemia (OR, 0.78; 95% CI 0.69,0.90, P<0.001) and lower limb amputation (OR, 0.83; 95% CI 0.71,0.98, P<0.001), …
← favours treatmentfavours comparator →
could be chanceCardiovascular events
OR 0.710.67–0.75
Cardiovascular events
OR 0.530.49–0.57
Cardiovascular events
OR 0.560.48–0.67
Cardiovascular events
OR 0.560.46–0.68
Cardiovascular events
OR 0.770.73–0.81
Cardiovascular events
OR 0.750.72–0.78
Cardiovascular events
OR 0.580.49–0.69
Hypoglycaemia
OR 0.780.69–0.90
Cardiovascular events
OR 0.830.71–0.98
SGLT2 inhibitorsOther glucose-loweringCardiovascular eventsHypoglycaemia
1 / 3